EffRx created Binosto® by taking this product from start to finish, including benefit assessment, formulation development, clinical development, FDA approval through a 505(b)(2) route, licensing to and launch via commercial partners. The approval and commercial launch of Binosto® provides EffRx with an important proof-of-concept and highlights a number of potential benefits of EffRx‘ technology. Proprietary Product
In-Licensed Rare Disease Products*
Alkindi® is an immediate-release hydrocortisone preparation that has been specifically designed to meet the dosing needs with adrenal insufficiency.
Bronchitol®, intended for people living with cystic fibrosis, is dry powder mannitol which is inhaled twice daily using a small handheld device.
Miglustat® is an inhibitor of glucosylceramide synthase. It’s therapeutic areas are Lysosomal Storage Diseases.
*Swiss Market